Wet AMD therapy seems safe in early data

San Francisco-Sirna Therapeutics' medication for the treatment of age-related macular degeneration (AMD) appears to be safe and well-tolerated, with all patients experiencing visual acuity stabilization so far, the company said.

In a report on interim data collected during the phase I trial for Sirna-027, the company said 14 patients who received a single intravitreal dose ranging from 100 to 800 µg have seen their vision stabilize during the trial.

The longest assessment has been 84 days.

The open-label, dose-escalation study is being conducted at the Wilmer Eye Institute at Johns Hopkins University, Baltimore; The Cole Eye Institute at the Cleveland Clinic; the Joint Clinical Research Center at Harvard University, Massachusetts Eye and Ear Infirmary, Boston; and the Jules Stein Eye Institute at the University of California, Los Angeles.